These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

220 related items for PubMed ID: 17602229

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Switching anti-TNF therapy in ankylosing spondylitis.
    Pradeep DJ, Keat AC, Gaffney K, Brooksby A, Leeder J, Harris C.
    Rheumatology (Oxford); 2008 Nov; 47(11):1726-7. PubMed ID: 18782856
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The impact of the NICE appraisal consultation document on anti-TNF therapy for ankylosing spondylitis.
    Smith N, Gadsby K, Butt S, Deighton C.
    Rheumatology (Oxford); 2007 Jun; 46(6):1044-5. PubMed ID: 17401132
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Do TNF-blockers reduce or induce uveitis?
    Cobo-Ibáñez T, del Carmen Ordóñez M, Muñoz-Fernández S, Madero-Prado R, Martín-Mola E.
    Rheumatology (Oxford); 2008 May; 47(5):731-2. PubMed ID: 18346974
    [No Abstract] [Full Text] [Related]

  • 9. Uveitis and tumour necrosis factor blockade in ankylosing spondylitis.
    Coates LC, McGonagle DG, Bennett AN, Emery P, Marzo-Ortega H.
    Ann Rheum Dis; 2008 May; 67(5):729-30. PubMed ID: 18408116
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. High disease activity of ankylosing spondylitis in the community before the introduction of tumour necrosis factor blockers.
    Hermann J, Müller T, Yazdani-Biuki B, Aringer M, Herold M, Ebner W, Ofner P, Graninger W.
    Ann Rheum Dis; 2007 Apr; 66(4):561-2. PubMed ID: 17360786
    [No Abstract] [Full Text] [Related]

  • 13. Could tumour necrosis factor blockers inhibit the progression of future structural damage in ankylosing spondylitis?
    Gaspersic N, Sersa I, Jevtic V, Tomsic M, Praprotnik S.
    Ann Rheum Dis; 2008 Sep; 67(9):1354. PubMed ID: 18697784
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005.
    Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Bijlsma JW, Dougados M, Emery P, Keystone EC, Klareskog L, Mease PJ.
    Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv2-14. PubMed ID: 16239380
    [No Abstract] [Full Text] [Related]

  • 17. Erythema multiforme with tumour necrosis factor inhibitors: a class effect?
    Kain T, MacGregor D, Buchanan RR, de Jager JP, Schachna L.
    Ann Rheum Dis; 2008 Jun; 67(6):899-900. PubMed ID: 18474663
    [No Abstract] [Full Text] [Related]

  • 18. Comparison of the Bath Ankylosing Spondylitis Disease Activity Index and a modified version of the index in assessing disease activity in patients with ankylosing spondylitis without peripheral manifestations.
    Song IH, Rudwaleit M, Listing J, Sieper J.
    Ann Rheum Dis; 2009 Nov; 68(11):1701-7. PubMed ID: 19029168
    [Abstract] [Full Text] [Related]

  • 19. Physical therapy in anti-TNF treated patients with ankylosing spondylitis.
    Dubey SG, Leeder J, Gaffney K.
    Rheumatology (Oxford); 2008 Jul; 47(7):1100-1. PubMed ID: 18495822
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.